Amundi lessened its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 38.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 636,281 shares of the life sciences company's stock after selling 400,093 shares during the quarter. Amundi owned 0.40% of Illumina worth $88,876,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. NS Partners Ltd boosted its holdings in shares of Illumina by 44.4% during the 4th quarter. NS Partners Ltd now owns 53,566 shares of the life sciences company's stock valued at $7,158,000 after acquiring an additional 16,463 shares in the last quarter. Generali Investments CEE investicni spolecnost a.s. acquired a new stake in shares of Illumina during the 4th quarter valued at $601,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina during the 4th quarter valued at $45,000. Edgestream Partners L.P. boosted its holdings in shares of Illumina by 94.1% during the 4th quarter. Edgestream Partners L.P. now owns 23,705 shares of the life sciences company's stock valued at $3,168,000 after acquiring an additional 11,493 shares in the last quarter. Finally, Prescott Group Capital Management L.L.C. boosted its holdings in shares of Illumina by 200.0% during the 4th quarter. Prescott Group Capital Management L.L.C. now owns 9,000 shares of the life sciences company's stock valued at $1,203,000 after acquiring an additional 6,000 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.
Illumina Stock Performance
Shares of ILMN opened at $84.52 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The stock has a 50-day moving average of $116.45 and a 200-day moving average of $130.84. The company has a market cap of $13.39 billion, a PE ratio of -11.01, a P/E/G ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a one year low of $80.18 and a one year high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on ILMN shares. Piper Sandler raised their price objective on Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Stephens reaffirmed an "overweight" rating and set a $156.00 target price on shares of Illumina in a research report on Tuesday. HSBC lowered Illumina from a "buy" rating to a "hold" rating and set a $100.00 target price for the company. in a research report on Friday, February 28th. Robert W. Baird lowered their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research report on Wednesday, March 5th. Finally, Guggenheim lowered their target price on Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $146.85.
Read Our Latest Analysis on ILMN
Illumina Company Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
